Comparison
Tirzepatide vs Urolithin A
Side-by-side of Tirzepatide and Urolithin A. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Tirzepatide
Tirzepatide for weight loss: dual GIP/GLP-1 agonist sold as Mounjaro and Zepbound. SURMOUNT-1 showed 22.5% mean body-weight loss at 15 mg over 72 weeks.
Urolithin A
Urolithin A supplement guide: pomegranate-derived metabolite, 500-1000 mg Mitopure dosing, mitophagy and muscle endurance evidence.
Effects at a glance
Tirzepatide
- •Dual GIP plus GLP-1 receptor agonist with a ~5-day half-life supporting once-weekly subcutaneous dosing
- •SURMOUNT-1 reported ~22.5% mean body-weight loss at 15 mg over 72 weeks versus 2.4% on placebo
- •Lowers HbA1c by ~1.9 to 2.6 percentage points in type 2 diabetes across SURPASS trials
- •Outperformed semaglutide 1.0 mg head-to-head on weight loss and HbA1c in SURPASS-2
- •GI effects (nausea, diarrhea, vomiting) drive most discontinuations and ease with slow titration
- •Lean-mass loss observed in body-composition substudies; resistance training and protein intake mitigate this
Urolithin A
- •Gut-microbiome-derived metabolite of pomegranate and walnut ellagitannins
- •Roughly 40% of adults are 'urolithin producers' from dietary intake; ~60% are non-producers
- •Ryu 2016 (Nature Medicine) reported lifespan extension in C. elegans and muscle benefits in aged rodents
- •Andreux 2019 first-in-human trial (n=60) established safety and mitochondrial gene-expression upregulation
- •Singh 2022 (n=66, 4 months, 1000 mg/day) reported improved muscle endurance in older adults
- •Most human trial portfolio is Amazentis-funded; independent replication is thin
Side-by-side
| Attribute | Tirzepatide | Urolithin A |
|---|---|---|
| Category | pharmaceutical | supplement |
| Also known as | Mounjaro, Zepbound, LY3298176 | UA, Mitopure, ellagitannin metabolite |
| Half-life (hr) ↗ | 120 | 17 |
| Typical dose (mg) ↗ | 10 | 500 |
| Dosing frequency | weekly | daily, morning with food |
| Routes | subcutaneous | oral |
| Onset (hr) | 24 | 2 |
| Peak (hr) | 72 | 4 |
| Molecular weight | 4813.45 | 228.2 |
| Molecular formula | C225H348N48O68 | C13H8O4 |
| Mechanism | Synthetic 39-amino-acid peptide that activates both GIP and GLP-1 receptors. Potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic and brainstem satiety circuits. | Induces mitophagy via potentiation of PINK1/Parkin signaling, leading to selective degradation of damaged mitochondria. Secondary anti-inflammatory effects via NF-kB modulation. |
| Legal status | Prescription only; FDA-approved 2022 (T2DM, Mounjaro) and 2023 (chronic weight management, Zepbound) | OTC dietary supplement (US GRAS 2018; EFSA Novel Food 2021) |
| WADA status | allowed | allowed |
| DEA / Rx | Rx only (not a controlled substance) | OTC supplement (not scheduled) |
| Pregnancy | Not recommended; discontinue 2 months before planned pregnancy | Insufficient data; not routinely recommended |
| CAS | 2023788-19-2 | 1143-70-0 |
| PubChem CID | 156588324 | 5488186 |
| Wikidata | Q105099794 | Q27101321 |
Safety profile
Tirzepatide
Common side effects
- nausea
- diarrhea
- vomiting
- constipation
- decreased appetite
- injection-site reactions
- fatigue
- abdominal pain
Contraindications
- personal or family history of medullary thyroid carcinoma
- multiple endocrine neoplasia type 2
- pregnancy
- history of pancreatitis (use caution)
- severe gastroparesis
Interactions
- insulin: additive hypoglycemia risk; insulin dose typically reduced(major)
- sulfonylureas (glipizide, glyburide): hypoglycemia risk, sulfonylurea dose often reduced(major)
- oral medications (general): delayed gastric emptying can alter absorption kinetics(moderate)
- oral contraceptives: reduced exposure after first dose; backup contraception recommended for 4 weeks after initiation and each dose escalation(moderate)
- warfarin: monitor INR due to altered absorption(moderate)
Urolithin A
Common side effects
- mild GI upset (rare)
- soft stools (rare)
Contraindications
- pregnancy and lactation (insufficient data)
- active chemotherapy (consult oncology)
Interactions
- chemotherapy agents: theoretical interaction with mitochondrial-targeting agents; consult oncologist(moderate)
Which Should You Take?
Urolithin A comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Tirzepatide is the right call when one of the conditionals below applies.
- → If your priority is metabolic health and glucose control, pick Tirzepatide.
- → If your priority is fat loss, pick Tirzepatide.
- → If your priority is healthspan extension, pick Urolithin A.
- → If your priority is muscle hypertrophy, pick Urolithin A.
Edge case: If you want to avoid prescription-only, Urolithin A is the more accessible choice.
Default choice: Urolithin A. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Tirzepatide only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Tirzepatide and Urolithin A?
Tirzepatide and Urolithin A differ in category (pharmaceutical vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Tirzepatide or Urolithin A?
Tirzepatide half-life is 120 hours; Urolithin A half-life is 17 hours.
Can you stack Tirzepatide with Urolithin A?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper